Frequently Asked Questions
The market is segmented based on , By Drugs (Phytonadione, Coagulation Factor Xa, Idarucizumab, and Others), Indication (Heparin Overdose, Reversal of Anticoagulation, and Others), Route of Administration (Oral and Injectable), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Anticoagulant Reversal Drugs Market size was valued at USD 989.00 USD Million in 2022.
The Global Anticoagulant Reversal Drugs Market is projected to grow at a CAGR of 15% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer, AstraZeneca, Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd, Endo International plc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Novartis AG, Lupin, Cipla , Aurobindo Pharma, Sanofi, Merck & Co. , Amneal Pharmaceuticals LLC., Alvogen, Bausch Health Companies .
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa.
